Veru, Inc. CEO Mitch Steiner Discusses Recent Enobosarm Data and Preserving Muscle While on GLP-1 Obesity Drugs

CEO Mitch Steiner joins us on this week’s WTR Biotech Spotlight to talk about the next generation of drugs focusing on lean mass (muscle) preservation for obesity patients on the popular GLP-1 therapies. He reviews the recent enobosarm Phase 2b data and highlights the importance of functional clinical benefit in addition to maintaining lean mass. Listen to learn more about Veru and its obesity drug enobosarm

Episode metadata supplied by the publisher feed · Published Feb 26, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Veru, Inc. CEO Mitch Steiner Discusses Recent Enobosarm Data and Preserving Muscle While on GLP-1 Obesity Drugs

0:00 34:32

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of WTR Healthcare Happenings?

This episode is 34 minutes long.

When was this WTR Healthcare Happenings episode published?

This episode was published on February 26, 2025.

Can I download this WTR Healthcare Happenings episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!